精華製藥(002349.SZ):子公司森萱醫藥新三板精選層掛牌申請獲全國股轉公司受理
格隆匯6月1日丨精華製藥(002349.SZ)公佈,公司控股子公司江蘇森萱醫藥股份有限公司(“森萱醫藥”)為全國中小企業股份轉讓系統(“新三板”)創新層掛牌企業,股票簡稱:森萱醫藥,股票代碼:830946,公司持有其84.14%股份。
森萱醫藥於2020年6月1日收到全國中小企業股份轉讓系統有限責任公司(“全國股轉公司”)出具的《受理通知書》(編號為:GF2020060002),經全國股轉公司審查,公司報送的股票公開發行並在精選層掛牌的申請文件符合相關要求,全國股轉公司決定予以受理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.